CALL/EVOTEC/40/0.1/20.06.25 Share Price

Warrant

DE000GP9V482

Real-time BOERSE MUENCHEN 07:56:10 27/05/2024 pm IST
0.036 EUR -2.70% Intraday chart for CALL/EVOTEC/40/0.1/20.06.25
Current month-5.13%
1 month-17.78%
Date Price Change
27/24/27 0.036 -2.70%
24/24/24 0.037 -2.63%
23/24/23 0.038 +2.70%
22/24/22 0.037 -2.63%
21/24/21 0.038 0.00%

Real-time BOERSE MUENCHEN

Last update May 27, 2024 at 07:56 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GP9V48
ISINDE000GP9V482
Date issued 20/07/2023
Strike 40
Maturity 20/06/2025 (389 Days)
Parity 10 : 1
Emission price 0.13
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.222
Lowest since issue 0.034
Spread 0.01
Spread %22.22%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.845 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.05%
Consensus